Should I buy or sell Agenus stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Agenus in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AGEN shares. View AGEN analyst ratings or view top-rated stocks .

What is Agenus' stock price target for 2024?

3 equities research analysts have issued 12-month price targets for Agenus' stock. Their AGEN share price targets range from $100.00 to $160.00. On average, they predict the company's stock price to reach $130.00 in the next year. This suggests a possible upside of 1,921.8% from the stock's current price. View analysts price targets for AGEN or view top-rated stocks among Wall Street analysts .

How have AGEN shares performed in 2024?

Agenus' stock was trading at $16.5580 at the start of the year. Since then, AGEN stock has decreased by 61.2% and is now trading at $6.43. View the best growth stocks for 2024 here .

When is Agenus' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our AGEN earnings forecast .

How were Agenus' earnings last quarter?

Agenus Inc. (NASDAQ:AGEN) announced its quarterly earnings results on Thursday, March, 14th. The biotechnology company reported ($2.60) EPS for the quarter, missing the consensus estimate of ($0.40) by $2.20. The biotechnology company earned $83.80 million during the quarter, compared to analysts' expectations of $54.21 million.

When did Agenus' stock split?

Agenus's stock reverse split before market open on Friday, April 12th 2024. The 1-20 reverse split was announced on Friday, April 12th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What is Garo H. Armen's approval rating as Agenus' CEO?

2 employees have rated Agenus Chief Executive Officer Garo H. Armen on Glassdoor.com . Garo H. Armen has an approval rating of 56% among the company's employees. This puts Garo H. Armen in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Agenus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Agenus investors own include (ROSG) (ROSG) , Exelixis (EXEL) , Sorrento Therapeutics (SRNE) , Dynavax Technologies (DVAX) , OPKO Health (OPK) , Inovio Pharmaceuticals (INO) , ADMA Biologics (ADMA) , Gilead Sciences (GILD) , Matinas BioPharma (MTNB) and RedHill Biopharma (RDHL) .

Who are Agenus' major shareholders?

Agenus' stock is owned by many different retail and institutional investors. Top institutional investors include Key Client Fiduciary Advisors LLC (4.10%), Powell Investment Advisors LLC (1.16%) and Los Angeles Capital Management LLC (0.04%). Insiders that own company stock include Agenus Inc, Christine M Klaskin , Garo H Armen and Steven J O'day . View institutional ownership trends .

How do I buy shares of Agenus?

Shares of AGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:AGEN

Agenus (AGEN) Stock Price, News & Analysis

→ Forget Nvidia, buy this A.I. Stock Now (From InvestorPlace) (Ad)

Free AGEN Stock Alerts

$6.39

-0.11 (-1.69%)

(As of 10:52 AM ET)

Compare

Today's Range: $6.16
▼
$6.98
50-Day Range: $6.50
▼
$18.56
52-Week Range: $6.16
▼
$42.60

Volume: 348,322 shs
Average Volume: 544,710 shs
Market Capitalization: $133.87 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $130.00

Get Agenus alerts:

Agenus MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1,921.8% Upside
$130.00 Price Target
Short Interest: Bearish
227.78% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.93
Upright™ Environmental Score
News Sentiment: -0.25
Based on 12 Articles This Week
Insider Trading: Acquiring Shares
$325,000 Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($8.20) to ($14.30) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.73 out of 5 stars

Medical Sector

240th out of 930 stocks

Biological Products, Except Diagnostic Industry

30th out of 155 stocks

3.5

Analyst's Opinion

Consensus Rating
Agenus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Agenus has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
227.78% of the outstanding shares of Agenus have been sold short.
Short Interest Ratio / Days to Cover
Agenus has a short interest ratio ("days to cover") of 4.5.
Change versus previous month
Short interest in Agenus has recently increased by 4.31%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Agenus does not currently pay a dividend.
Dividend Growth
Agenus does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Agenus has received a 72.61% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer" and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Agenus is -0.93.

2.1

News and Social Media Coverage

News Sentiment
Agenus has a news sentiment score of -0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 12 news articles for Agenus this week, compared to 2 articles on an average week.
Search Interest
65 people have searched for AGEN on MarketBeat in the last 30 days. This is an increase of 18% compared to the previous 30 days.
MarketBeat Follows
25 people have added Agenus to their MarketBeat watchlist in the last 30 days. This is an increase of 9% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Agenus insiders have bought more of their company's stock than they have sold. Specifically, they have bought $325,000.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 4.80% of the stock of Agenus is held by insiders.
Percentage Held by Institutions
61.46% of the stock of Agenus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Agenus are expected to decrease in the coming year, from ($8.20) to ($14.30) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Agenus is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Agenus is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

“Forget Tesla, this is Elon’s Next Big Thing”

According to Forbes, this breakthrough could define the future of AI. Most people don’t know about it… Because it was found 750 miles away from Silicon Valley.

Click here to see the details.

About Agenus Stock (NASDAQ:AGEN)

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

AGEN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

AGEN Stock News Headlines

April 14, 2024 | americanbankingnews.com

Agenus (NASDAQ:AGEN) Sets New 1-Year Low at $8.10

April 13, 2024 | nasdaq.com

Commit To Purchase Agenus At $1, Earn 2607.1% Annualized Using Options

April 16, 2024 | InvestorPlace (Ad)

REVEALED: Elon Musk’s Secret A.I. Facility?

I recently shot this video outside what could be Elon Musk’s biggest secret. What’s happening inside these walls is so important that our government has declared it a matter of national security.

April 12, 2024 | markets.businessinsider.com

Small-Cap Cancer Drug Developer Agenus' Highlights Encouraging Data From Colorectal Cancer, But Funding Concerns Loom

April 12, 2024 | nasdaq.com

Agenus Updates Phase 1 Data Of BOT/BAL Therapy In MSS Metastatic Colorectal Cancer

April 12, 2024 | markets.businessinsider.com

Agenus Stock Falls After Reporting Updated Phase 1 Data On Colorectal Cancer Therapy

April 12, 2024 | msn.com

Agenus reports updated Phase 1 data on colorectal cancer therapy

April 12, 2024 | finance.yahoo.com

Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer

April 16, 2024 | InvestorPlace (Ad)

REVEALED: Elon Musk’s Secret A.I. Facility?

I recently shot this video outside what could be Elon Musk’s biggest secret. What’s happening inside these walls is so important that our government has declared it a matter of national security.

April 12, 2024 | businesswire.com

Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer

April 10, 2024 | americanbankingnews.com

Agenus Stock Scheduled to Reverse Split on Friday, April 12th (NASDAQ:AGEN)

April 8, 2024 | marketwatch.com

MiNK Therapeutics' MiNK-215 Data Show Potential Treatment for Liver Metastases

April 8, 2024 | fool.com

Down 75%. Is Agenus Stock a Buy on the Dip?

April 7, 2024 | investing.com

Agenus announces reverse stock split to meet Nasdaq requirements

April 5, 2024 | businesswire.com

Agenus Announces Reverse Stock Split of Common Stock

April 3, 2024 | fool.com

2 Stocks That Could More Than Double Your Money, According to Wall Street: Are They Buys Now?

March 24, 2024 | investorplace.com

3 Mind-Blowing Stocks That Could Turn $1,000 Into $1 Million

March 20, 2024 | ca.finance.yahoo.com

AGEN Aug 2024 2.000 put

March 17, 2024 | finance.yahoo.com

US$5.50: That's What Analysts Think Agenus Inc. (NASDAQ:AGEN) Is Worth After Its Latest Results

March 16, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Agenus Amidst Promising Cancer Immunotherapy Developments and Strategic Financial Moves

March 15, 2024 | benzinga.com

Earnings Preview For Agenus

March 15, 2024 | finance.yahoo.com

Agenus Inc. (NASDAQ:AGEN) Q4 2023 Earnings Call Transcript

March 15, 2024 | finance.yahoo.com

Analysts Just Shaved Their Agenus Inc. (NASDAQ:AGEN) Forecasts Dramatically

March 15, 2024 | ca.finance.yahoo.com

AGEN Mar 2024 2.000 put

March 14, 2024 | markets.businessinsider.com

Agenus Poised for Growth: Anticipated BLA Filing and Promising Clinical Data Underpin Buy Rating

March 14, 2024 | finance.yahoo.com

Dogecoin spikes after Musk hints at Tesla payment option

March 14, 2024 | fool.com

Agenus (AGEN) Q4 2023 Earnings Call Transcript

See More Headlines

Receive AGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Agenus and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/14/2024
Today: 4/16/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: Biotechnology
Current Symbol: NASDAQ:AGEN
CUSIP: 00847G70
CIK: 1098972
Web: agenusbio.com
Phone: (781) 674-4400
Fax: 781-674-4200
Employees: 389
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $130.00
High Stock Price Target: $160.00
Low Stock Price Target: $100.00
Potential Upside/Downside: +1,900.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($14.20)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-245,760,000.00
Net Margins: -164.69%
Pretax Margin: -164.69%
Return on Equity: N/A
Return on Assets: -71.22%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.44
Quick Ratio: 0.44

Sales & Book Value

Annual Sales: $156.31 million
Price / Sales: 0.87
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($7.78) per share
Price / Book: -0.84

Miscellaneous

Outstanding Shares: 20,950,000
Free Float: 19,941,000
Market Cap: $136.18 million
Optionable: Optionable
Beta: 1.26

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Dr. Garo H. Armen Ph.D. (Age 71)
Founder, Executive Chairman & CEO
Comp: $1.34M
Ms. Christine M. Klaskin (Age 58)
VP of Finance, Principal Financial Officer & Principal Accounting Officer
Comp: $407.44k
Dr. Steven J. O'Day M.D. (Age 63)
Ph.D., Chief Medical Officer
Comp: $970.98k
Craig Winter
Chief Information Officer
Mr. Zack Armen
Head of Investor Relations
Ms. Tracy Mazza Clemente
Chief People Officer
Mr. Dhan Chand
Scientific Director & Head of Drug Discovery
Mr. Alfred Dadson
Chief Manufacturing Officer
Mr. Eric Humes
Chief Quality Officer
Dr. Todd Jude Yancey M.D.
Member of Advisory Board & Chief Strategic Advisor

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AGEN Stock Analysis - Frequently Asked Questions

Should I buy or sell Agenus stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Agenus in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AGEN shares.
View AGEN analyst ratings or view top-rated stocks.
What is Agenus' stock price target for 2024?: 3 equities research analysts have issued 12-month price targets for Agenus' stock. Their AGEN share price targets range from $100.00 to $160.00. On average, they predict the company's stock price to reach $130.00 in the next year. This suggests a possible upside of 1,921.8% from the stock's current price.
View analysts price targets for AGEN or view top-rated stocks among Wall Street analysts.
How have AGEN shares performed in 2024?: Agenus' stock was trading at $16.5580 at the start of the year. Since then, AGEN stock has decreased by 61.2% and is now trading at $6.43.
View the best growth stocks for 2024 here.
When is Agenus' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our AGEN earnings forecast.
How were Agenus' earnings last quarter?: Agenus Inc. (NASDAQ:AGEN) announced its quarterly earnings results on Thursday, March, 14th. The biotechnology company reported ($2.60) EPS for the quarter, missing the consensus estimate of ($0.40) by $2.20. The biotechnology company earned $83.80 million during the quarter, compared to analysts' expectations of $54.21 million.
When did Agenus' stock split?: Agenus's stock reverse split before market open on Friday, April 12th 2024. The 1-20 reverse split was announced on Friday, April 12th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What is Garo H. Armen's approval rating as Agenus' CEO?: 2 employees have rated Agenus Chief Executive Officer Garo H. Armen on Glassdoor.com. Garo H. Armen has an approval rating of 56% among the company's employees. This puts Garo H. Armen in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Agenus own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Agenus investors own include (ROSG) (ROSG), Exelixis (EXEL), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), OPKO Health (OPK), Inovio Pharmaceuticals (INO), ADMA Biologics (ADMA), Gilead Sciences (GILD), Matinas BioPharma (MTNB) and RedHill Biopharma (RDHL).
Who are Agenus' major shareholders?: Agenus' stock is owned by many different retail and institutional investors. Top institutional investors include Key Client Fiduciary Advisors LLC (4.10%), Powell Investment Advisors LLC (1.16%) and Los Angeles Capital Management LLC (0.04%). Insiders that own company stock include Agenus Inc, Christine M Klaskin, Garo H Armen and Steven J O'day.
View institutional ownership trends.
How do I buy shares of Agenus?: Shares of AGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AGEN) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial